FDA agrees to review Takeda and Affymax's anemia drug

07/27/2011 | Xconomy

Affymax and Takeda Pharmaceutical's drug candidate peginesitide was accepted for FDA review. Formerly named Hematide, the once-monthly drug is intended for anemia in kidney patients on dialysis.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ